Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDK-activating kinase assembly factor MAT1 (also known as MNAT1) is an essential protein component of the CDK-activating kinase (CAK) complex, which also includes cyclin H and CDK7[1][2][3]. MAT1 stabilizes the interaction between CDK7 and cyclin H, forming a heterotrimeric complex fundamental for both cell cycle progression and transcription initiation by RNA polymerase II[2][3]. Within the CAK complex, MAT1 enhances the kinase’s ability to phosphorylate CDKs and the C-terminal domain (CTD) of RNA polymerase II, thereby regulating entry into cell cycle and transcriptional activity[1][2][3]. CAK, and specifically the MAT1 subunit, has gained therapeutic interest, particularly for targeting cancers highly dependent on transcriptional regulation; small molecule inhibitors such as THZ1 covalently inhibit CDK7 activity within CAK[2][3]. Defects or dysregulation in MAT1-containing complexes are linked to diseases including cancer and Cockayne syndrome[1].
Irreversible inhibition of kinase activity (by targeting CDK7 active site, e.g., THZ1) Disruption of cell cycle progression and transcription by RNA polymerase II
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDK-activating kinase assembly factor MAT1 (MAT1).